Nothing Special   »   [go: up one dir, main page]

WO2012028834A1 - Utilisation de bupropion dans le traitement d'une dysfonction sexuelle - Google Patents

Utilisation de bupropion dans le traitement d'une dysfonction sexuelle Download PDF

Info

Publication number
WO2012028834A1
WO2012028834A1 PCT/GB2010/001649 GB2010001649W WO2012028834A1 WO 2012028834 A1 WO2012028834 A1 WO 2012028834A1 GB 2010001649 W GB2010001649 W GB 2010001649W WO 2012028834 A1 WO2012028834 A1 WO 2012028834A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
bupropion
sexual desire
acid addition
desire
Prior art date
Application number
PCT/GB2010/001649
Other languages
English (en)
Inventor
Marcel Petrus Maria Bartels
David Llewellyn
Original Assignee
Marcel Petrus Maria Bartels
David Llewellyn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marcel Petrus Maria Bartels, David Llewellyn filed Critical Marcel Petrus Maria Bartels
Priority to PCT/GB2010/001649 priority Critical patent/WO2012028834A1/fr
Publication of WO2012028834A1 publication Critical patent/WO2012028834A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Definitions

  • the invention relates to the use of BUPROPION also known as
  • the compound ( ⁇ )-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one has been used as an antidepressant and lately as an anti smoking medication.
  • certain side effects came to light which included a heightening of sexual desire and ability to reach orgasm particularly in females.
  • Bupropion acts as a dopamine reuptake inhibitor ( DRI ) norepinephrine reuptake inhibitor ( RI ) and as a nicotinic acetylcholine receptor agonist. It is therefore well suited as an antidepressant for which it has been previously prescribed and as the anti smoking aid that it is presently prescribed for.
  • the instant invention relates to the use of BUPROPION, optionally in form of the pharmalogically accepted acid addition salts thereof for the preparation of a medicament for the treatment of disorders of sexual desire.
  • the invention relates to the use of BUPROPION, optionally in form of the pharmalogically accepted acid addition salts thereof for the preparation of a medicament for the treatment of disorders selected from the group consisting of HYPOACTIVE SEXUAL DESIRE DISORDER, loss of sexual desire, lack of sexual desire, deaeased sexual desire, inhibited sexual desire, loss of libido, libido disturbance and frigidity.
  • BUPROPION optionally in form of the pharmalogically accepted acid addition salts thereof for the preparation of a medicament for the treatment of disorders selected from the group consisting of
  • the invention relates to the use of BUPROPION, optionally in form of the pharmalogically accepted add addition salts thereof for the preparation of a medicament for the treatment of disorders selected from the group consisting of HYPOACTIVE SEXUAL DESIRE DISORDER and loss of sexual desire,
  • BUPROPION optionally in form of the pharmalogically accepted acid addition salts thereof for the preparation of a medicament for the treatment of female sexual dysfunction is preferred.
  • BUPROPION can be optionally used in the form of pharmaceutically acceptable acid addition salts.
  • Suitable acid addition salts include, for example, those of the acids selected from, succinic acid, hydrobromic acid.acetic acid, fumaric acid, maleic acid, methanesuphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, and citric acid. Mixtures of the above mentioned acid addition salts can also be used. From the aforementoned acid addition salts the hydrochloride and the hydrobromide, particulairly the hydrochloride, are preferred.
  • BUPROPION optionally used in the form of pharmaceutically acceptable acid addition salts may be incorporated into the conventional pharmaceutical preparation in solid liquid or spray form.
  • the composition may, for example, be presented in a form suitable for oral, rectal, parental administration, or for nasal inhalation.
  • Preferred forms include for example, capsules, tablets, coated tablets, ampoules, suppositories and nasal spray.
  • the active ingredient may be incorporated in excipients and carriers conventionally used in pharmaceutical compositions such as, for example, talc, arabic gum, lactose, gelatine, magnesium stearate, corn starch, aqueous or non-aqueous vehicles, polyvinyl pyrolidone, semi-synthetic glycerides of fatty acids, benzalconium chloride, sodium phosphate, EDTA, polysorbate 80.
  • the compositions- are advantageously formulated in doseage units each doseage unit being adapted to supply a single dose of the active ingredient.
  • the dosis range applicable per day is between 0.1 mg to 1000mg, preferably between 1.0mg and 900mg, more preferably between 10mg and 800mg.
  • Each doseage unit may conveniently contain from 0.25mg to 300mg, preferably 1 mg to 200mg.
  • Suitable tablets may be obtained, for example, by mixing the active substances with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate, or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and / oragents for delaying release such as carboxymethyl cellulose, cellulose acetate phthalate or polyvinyl acetate.
  • excipients for example inert diluents such as calcium carbonate, calcium phosphate, or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and / oragents for delaying release such as carboxymethyl cellulose, cellulose acetate phthalate or polyvinyl acetate.
  • the tablets may also comprise several layers.
  • Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellack, gum arabic, talc , titanium dioxide or sugar.
  • substances normally used for tablet coatings for example collidone or shellack, gum arabic, talc , titanium dioxide or sugar.
  • the core may also consist of a number of layers to achieve the delayed release, possibly using the excipients mentioned above for the tablets.
  • Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar and a flavour enhancer eg
  • flavouring such as vanilla or orange extract.
  • suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols
  • preservatives such as p-hydroxybenzoates or stabilisers such as alkali metal saltsof ethylenediamine tetra acetic acid, and transferred to into injection vials or ampoules.
  • Capsules containing one or more active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
  • Suitable suppositories may be made for example by mixing with carriers provided this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
  • the finely ground active substance, lactose and some of the corn starch are mixed together.
  • the mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried.
  • the granules, the remaining corn starch and the magnesium stearate are screened and mixed together.
  • the mixture is compressed to produce tablets of a suitable shape and size.
  • the finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and workedwith the remaining corn starch and water to form a granulate which is dried and screened.
  • the sodium carboxymethyl starch and the magnesium stearate are added and mixed inand the mixture is compressed to form tablets of a suitable size.
  • the active substance, corn starch, lactose, and polyvinylpyrrolidone are thoroughly mixed and moistened with water.
  • the moist mass is pushed through a screenwith a 1mm mesh size, dried at 45 degrees C and the granules are then passed through the same screen.
  • convextablet cores with a diameter of 6mm are compressed in a tablet-making machine.
  • the tablet cores thus produced are coated in known manner with a covering consisting of sugar and talc.
  • the finished coated tablets are polished with wax.
  • the substance and corn starch are mixed and moistened with water.
  • the moist mass is screened and dried.
  • the dry granules are screened and mixed withmagnesium stearate.
  • the finished mixture is packed into size 1 hard gelatine capsules.
  • the active substance is dissolved in water at its own pH or optionally at pH 5.5 -6.5 and sodium chloride is added to make it isotonic.
  • the solution obtained is filtered free from pyrogens and the filtrate is transferred under
  • the hard fat is melted. At 40 degrees C the ground active substance is homogenously dispersed. It is cooled to 38 degrees C and poured into slightly chilled suppository moulds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur l'utilisation de bupropion (±)-2-(tert-buty1amino)-1-(3-chlorophényl)propan-1-one et de ses formes isomères (++) et (--) ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ceux-ci, pour le traitement de troubles du désir sexuel, en particulier, bien que non exclusivement, pour des patients de sexe féminin. L'invention porte sur l'amélioration physique de l'orgasme chez des patients qui jusqu'à présent ont eu des difficultés à atteindre une satisfaction sexuelle.
PCT/GB2010/001649 2010-09-01 2010-09-01 Utilisation de bupropion dans le traitement d'une dysfonction sexuelle WO2012028834A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/GB2010/001649 WO2012028834A1 (fr) 2010-09-01 2010-09-01 Utilisation de bupropion dans le traitement d'une dysfonction sexuelle

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2010/001649 WO2012028834A1 (fr) 2010-09-01 2010-09-01 Utilisation de bupropion dans le traitement d'une dysfonction sexuelle

Publications (1)

Publication Number Publication Date
WO2012028834A1 true WO2012028834A1 (fr) 2012-03-08

Family

ID=43838063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/001649 WO2012028834A1 (fr) 2010-09-01 2010-09-01 Utilisation de bupropion dans le traitement d'une dysfonction sexuelle

Country Status (1)

Country Link
WO (1) WO2012028834A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062257A2 (fr) * 2000-02-22 2001-08-30 Sepracor Inc. Metabolites du bupropion et leurs procedes de synthese et d"utilisation
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2007006738A2 (fr) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Composition pharmaceutique utile dans le traitement des troubles de la libido
US20070203231A1 (en) * 2005-10-14 2007-08-30 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20100143256A1 (en) * 2001-07-11 2010-06-10 Cns Response, Inc. Electroencephalography based systems and methods for selecting therapies and predicting outcomes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062257A2 (fr) * 2000-02-22 2001-08-30 Sepracor Inc. Metabolites du bupropion et leurs procedes de synthese et d"utilisation
US20100143256A1 (en) * 2001-07-11 2010-06-10 Cns Response, Inc. Electroencephalography based systems and methods for selecting therapies and predicting outcomes
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2007006738A2 (fr) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Composition pharmaceutique utile dans le traitement des troubles de la libido
US20070203231A1 (en) * 2005-10-14 2007-08-30 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASHTON A K ET AL: "BUPROPION AS AN ANTIDOTE FOR SEROTONIN REUPTAKE INHIBITOR-INDUCED SEXUAL DYSFUNCTION", JOURNAL OF CLINICAL PSYCHIATRY, PHYSICIANS POSTGRADUATE PRESS, INC, US, vol. 59, no. 3, 1 January 1998 (1998-01-01), pages 112 - 115, XP009074758, ISSN: 0160-6689 *
GINZBURG REGINA ET AL: "EFFECT OF BUPROPION ON SEXUAL DYSFUNCTION", ANNALS OF PHARMACOTHERAPY, HARVEY WHITNEY BOOKS COMPANY, vol. 39, no. 12, 1 January 2005 (2005-01-01), pages 2096 - 2099, XP009074744, ISSN: 1060-0280, DOI: DOI:10.1345/APH.1G275 *
LABBATE L A: "BUPROPION-SR-INDUCED INCREASED LIBIDO AND SPONTANEOUS ORGASM", CANADIAN JOURNAL OF PSYCHIATRY. REVUE CANADIENNE DEPSYCHIATRIE, CANADIAN PSYCHIATRIC ASSOCIATION, OTTAWA, CA, vol. 43, no. 5, 1 August 1998 (1998-08-01), pages 644/645, XP000972458, ISSN: 0706-7437 *
SEGRAVES ROBERT TAYLOR ET AL: "Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 24, no. 3, June 2004 (2004-06-01), pages 339 - 342, XP009147325, ISSN: 0271-0749 *

Similar Documents

Publication Publication Date Title
US10307420B2 (en) Treating sexual desire disorders with flibanserin
US20070265276A1 (en) Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders
CA2563167C (fr) Utilisation de flibanserine dans le traitement de troubles premenstruels et d'autres troubles sexuels chez la femme
AU2002333894A1 (en) Use of flibanserin in the treatment of sexual disorders
WO2012028834A1 (fr) Utilisation de bupropion dans le traitement d'une dysfonction sexuelle
US10675280B2 (en) Treating sexual desire disorders with flibanserin
JP2010518040A (ja) 不眠症を治療するためのフリバンセリンの使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10765826

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10765826

Country of ref document: EP

Kind code of ref document: A1